

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**RAJYA SABHA
UNSTARRED QUESTION NO.277
TO BE ANSWERED ON 20th July, 2021**

DELAY IN PRODUCTION OF DRDO ANTI-COVID 2G DRUG

277 SHRI T.G. VENKATESH:

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) whether it is a fact that Government is delaying the production of DRDO Anti-COVID 2G Drug in spite of 40+ drug production companies coming forward to produce it and not even completed the verification of their applications so far;
- (b) if so, the details thereof; and
- (c) the reasons therefor?

**ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND
FAMILY WELFARE
(DR. BHARATI PRAVIN PAWAR)**

(a) to (c): No. 2-Deoxy-D-Glucose (2-DG) is a New drug under the provisions of “New Drugs and Clinical Trial Rules, 2019”. For manufacturing and marketing of 2-DG, new drug permission is required under the provisions of “New Drugs and Clinical Trials Rules, 2019”. Accordingly, the manufacturers are required to submit the application to Central Drugs Standard Control Organization (CDSCO) as per the above rules. Such applications as and when received are processed as per Rules.

Approval for manufacture of 2-Deoxy-D-Glucose (2-DG) was initially granted by CDSCO to Dr. Reddy’s Lab. CDSCO has received only four applications subsequently for 2-DG formulations which have been processed by CDSCO under the provisions of New Drugs and Clinical Trials Rules, 2019, and actions like issuance of NOC for lab testing etc. have been taken.